Skip to main content

Skadden, Arps, Slate, Meagher & Flom and Zhong Lun Law Firm have advised China’s Everest Medicines on its $451 million IPO in Hong Kong, with Kirkland & Ellis and Tian Yuan Law Firm advising the joint sponsors and underwriters.

Everest Medicines, a China-based clinical-stage biopharmaceutical company created by C-Bridge Capital in July 2017, develops, licenses and commercialises potentially novel transformative therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets.

It is the second Chinese biopharmaceutical company to go public in Hong Kong this month, after JHBP (CY) Holdings.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

N&A, S&C, TMI advise as Japan's Nidec makes $1.6 bln bid for Makino Milling

by Asian Legal Business《亚洲法律杂志》 |

TMI Associates, Freshfields and Davis Polk & Wardwell have represented Japanese manufacturing giant Nidec on its 257-billion-yen ($1.6 billion) bid for Makino Milling Machine, which turned to Nishimura & Asahi and Sullivan & Cromwell for advice.

Deals

N&A, MHM, Skadden, STB guide JX Advanced Metal’s $3 bln Japan IPO

by Nimitt Dixit |

Nishimura & Asahi and Skadden Arps Slate Meagher & Flom are advising JX Advanced Metals on its upcoming 460-billion-yen ($3 billion) initial public offering, the largest listing in Japan since SoftBank Corp’s $23.5 billion IPO in 2018.

Deals

Trilegal, Touchstone, CAM act on Carlyle’s $400 mln entry into India auto-components space

by Nimitt Dixit |

Trilegal has advised global private equity firm Carlyle on its acquisition of majority stakes in Highway Industries (HIL) and Roop Automotives for $400 million, marking its entry into India's auto components sector through a new manufacturing platform.